Entrada Therapeutics, Inc.
Clinical trials sponsored by Entrada Therapeutics, Inc., explained in plain language.
-
New hope for duchenne: experimental drug ENTR-601-45 enters human trials
Disease control Recruiting nowThis study tests an investigational drug called ENTR-601-45 in people with Duchenne muscular dystrophy (DMD) who have a specific genetic change (exon 45 skipping). The goal is to check the drug's safety, find the right dose, and see if it can help muscles work better. About 24 ma…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for duchenne: experimental drug targets genetic flaw
Disease control Recruiting nowThis study tests an investigational drug called ENTR-601-44 in 24 boys and young men with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by skipping a specific part of the gene (exon 44). The trial has two parts: first, to find the safest and most effecti…
Phase: PHASE1, PHASE2 • Sponsor: Entrada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC